Clicky

Orion Oyj A(ORNAV) News

Date Title
Jul 21 Darolutamide receives EU approval in third indication for patients with advanced prostate cancer
Jul 18 Orion Group Half-Year Financial Report January–June 2025
Jul 18 Orion Corporation’s financial reporting and Annual General Meeting in 2026
Jun 23 141,959 Orion Corporation A shares converted into B shares
Jun 20 CHMP recommends third indication for darolutamide for patients with advanced prostate cancer
Jun 17 Orion and Glykos announce the extension of their research collaboration and licensing agreement for the development of next-generation ADCs
Apr 10 The Helsinki Court of Appeal sentenced a member of Orion's Board of Directors to a fine for a securities market information offence
Apr 9 Orion publishes Interim Report for January–March 2025 and holds a webcast on 23 April 2025
Jan 2 3 Leading Dividend Stocks Yielding Up To 8.5%
Dec 30 Orion and Marinus terminate agreement for ganaxolone in Europe
Jul 25 Orion publishes Half-Year Financial Report for January–June 2024 and holds a webcast on 8 August 2024
Feb 19 Orion to investigate the possible outsourcing of its pharmaceutical production in Kuopio, Finland
Jan 11 Recommendation by the Orion Nomination Committee on the proposals to be submitted to the 2024 Annual General Meeting
Jan 11 Insurance portfolio of Orion Pension Fund’s B fund transferred to an external pension insurance company – the transfer has approximately EUR 31 million positive impact on Orion’s result in 2023
Dec 4 87 000 Orion Corporation A shares converted into B shares
Oct 26 Orion Group Interim Report January–September 2023
Sep 20 Change in Orion Group's Half-Year Financial Report 2024 publication date
Aug 22 Change in Orion Group Executive Management Board as of February 1st, 2024 – Julia Macharey appointed Senior Vice President, People & Culture
Jul 19 Orion Corporation: Managers’ transactions – Veli-Matti Mattila
Jul 17 Orion Group Half-Year Financial Report 1–6/2023